Literature DB >> 15134622

Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors.

German G Gomez1, Susana B Read, Lazaro E Gerschenson, Daniela Santoli, Adam Zweifach, Carol A Kruse.   

Abstract

TALL-104 is a human leukemic T cell line that expresses markers characteristic of both cytotoxic T lymphocytes and natural killer cells. TALL-104 cells are potent tumor killers, and the use of lethally irradiated TALL-104 as cellular therapy for a variety of tumors has been explored. We investigated the interactions of TALL-104 cells with human brain tumor cells. TALL-104 cells mediated increased lysis of a panel of brain tumor cells at low effector-to-target ratios over time. We obtained evidence that TALL-104 cells injured glioma cells by both apoptotic and necrotic pathways. A 7-amino actinomycin D flow cytometry assay revealed that the percentages of both apoptotic and necrotic glioma cells increased after TALL-104 cell/glioma cell coincubations. Fluorescent microscopy studies and a quantitative morphologic assay confirmed that TALL-104 cell/glioma cell interactions resulted in tumor cell apoptosis. Cytokines are secreted when TALL-104 cells are coincubated with brain tumor cells; however, morphologic analysis assays revealed that the soluble factors contained within clarified supernates obtained from 4 h coincubates added back to brain tumor cell cultures did not trigger the glioma apoptosis. TALL-104 cells do not express Fas ligand, even upon coincubation with glioma targets, which suggests that the Fas/Fas ligand apoptotic pathway is not likely responsible for the cell injury observed. We obtained evidence that cell injury is calcium dependent and that lytic granule exocytosis is triggered by contact of TALL-104 cells with human glioma cells, suggesting that this pathway mediates glioma cell apoptosis and necrosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15134622      PMCID: PMC1871983          DOI: 10.1215/s1152851703000140

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  48 in total

1.  Paucity of retinoic acid receptor alpha (RAR alpha) nuclear immunostaining in gliomas and inability of retinoic acid to influence neural cell adhesion molecule (NCAM) expression.

Authors:  B K Kleinschmidt-DeMasters; E A Orr; E Savelieva; G C Owens; C A Kruse
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  Central nervous system tumors: what have we learned and where are we heading?

Authors:  E R Laws
Journal:  CA Cancer J Clin       Date:  1998 Nov-Dec       Impact factor: 508.702

3.  Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours.

Authors:  C A Kruse; L T Beck
Journal:  Biotechnol Appl Biochem       Date:  1997-06       Impact factor: 2.431

4.  Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2.

Authors:  C A Kruse; L Cepeda; B Owens; S D Johnson; J Stears; K O Lillehei
Journal:  Cancer Immunol Immunother       Date:  1997-10       Impact factor: 6.968

5.  Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells.

Authors:  G Bossi; G M Griffiths
Journal:  Nat Med       Date:  1999-01       Impact factor: 53.440

Review 6.  Primary central nervous system tumors: advances in knowledge and treatment.

Authors:  M D Prados; M S Berger; C B Wilson
Journal:  CA Cancer J Clin       Date:  1998 Nov-Dec       Impact factor: 508.702

7.  The regulation of CD95 ligand expression and function in CTL.

Authors:  J H Li; D Rosen; D Ronen; C K Behrens; P H Krammer; W R Clark; G Berke
Journal:  J Immunol       Date:  1998-10-15       Impact factor: 5.422

8.  Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104.

Authors:  S Visonneau; A Cesano; T Tran; K A Jeglum; D Santoli
Journal:  Clin Cancer Res       Date:  1997-10       Impact factor: 12.531

9.  Tumor necrosis factor-alpha-induced cell killing and activation of transcription factor NF-kappaB are uncoupled in L929 cells.

Authors:  S P Hehner; T G Hofmann; F Ratter; A Dumont; W Dröge; M L Schmitz
Journal:  J Biol Chem       Date:  1998-07-17       Impact factor: 5.157

10.  Receptor expression, cytogenetic, and molecular analysis of six continuous human glioma cell lines.

Authors:  C A Kruse; M Varella-Garcia; B K Kleinschmidt-Demasters; G C Owens; E B Spector; H Fakhrai; E Savelieva; B C Liang
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-06       Impact factor: 2.723

View more
  11 in total

1.  Implementing preclinical study findings to protocol design: translational studies with alloreactive CTL for gliomas.

Authors:  Michelle J Hickey; Colin C Malone; Kate E Erickson; German G Gomez; Emma L Young; Linda M Liau; Robert M Prins; Carol A Kruse
Journal:  Am J Transl Res       Date:  2012-01-10       Impact factor: 4.060

2.  siRNA Down-regulation of the PATZ1 Gene in Human Glioma Cells Increases Their Sensitivity to Apoptotic Stimuli.

Authors:  Richard Tritz; Barbara M Mueller; Michelle J Hickey; Amy H Lin; German G Gomez; Philipp Hadwiger; Dinah W Y Sah; Leslie Muldoon; Edward A Neuwelt; Carol A Kruse
Journal:  Cancer Ther       Date:  2008

3.  Glioma cell integrin expression and their interactions with integrin antagonists: Research Article.

Authors:  Ralph-Heiko Mattern; Susana B Read; Michael D Pierschbacher; Chun-I Sze; Brian P Eliceiri; Carol A Kruse
Journal:  Cancer Ther       Date:  2005

4.  Catalytic nucleic acid enzymes for the study and development of therapies in the central nervous system: Review Article.

Authors:  Richard Tritz; Cellia Habita; Joan M Robbins; German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2005

5.  Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization.

Authors:  German G Gomez; Marileila Varella-Garcia; Carol A Kruse
Journal:  Cancer Genet Cytogenet       Date:  2006-03

6.  Immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes: downregulation of multiple proapoptotic factors.

Authors:  German G Gomez; Michelle J Hickey; Richard Tritz; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2008-06

7.  Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.

Authors:  German G Gomez; Carol A Kruse
Journal:  J Immunother       Date:  2007-04       Impact factor: 4.456

8.  Global Reduction of H3K4me3 Improves Chemotherapeutic Efficacy for Pediatric Ependymomas.

Authors:  Rebecca Lewis; Yuping D Li; Lindsey Hoffman; Rintaro Hashizume; Gordan Gravohac; Gavin Rice; Nitin R Wadhwani; Chunfa Jie; Tatiana Pundy; Barbara Mania-Farnell; Chandra S Mayanil; Marcelo B Soares; Ting Lei; Charles D James; Nicolas K Foreman; Tadanori Tomita; Guifa Xi
Journal:  Neoplasia       Date:  2019-04-18       Impact factor: 5.715

9.  CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro.

Authors:  Patrick N Song; Ameer Mansur; Kari J Dugger; Tessa R Davis; Grant Howard; Thomas E Yankeelov; Anna G Sorace
Journal:  Cancer Cell Int       Date:  2020-11-10       Impact factor: 5.722

10.  Anti-Yo antibody-positive paraneoplastic cerebellar degeneration in a patient with possible cholangiocarcinoma: A case report and review of the literature.

Authors:  Yue Lou; Shan-Hu Xu; Si-Ran Zhang; Qin-Fen Shu; Xiao-Li Liu
Journal:  World J Clin Cases       Date:  2021-06-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.